key: cord-0771436-e4blflxy
authors: Hartzell, Susan; Bin, Sofia; Benedetti, Claudia; Haverly, Meredith; Gallon, Lorenzo; Zaza, Gianluigi; Riella, Leonardo V.; Menon, Madhav C.; Florman, Sander; Rahman, Adeeb H.; Leech, John M.; Heeger, Peter S.; Cravedi, Paolo
title: Evidence of potent humoral immune activity in COVID19‐infected kidney transplant recipients
date: 2020-08-12
journal: Am J Transplant
DOI: 10.1111/ajt.16261
sha: 30b7a6e70bf11009ef15cf8d14c4392e3ba2ff09
doc_id: 771436
cord_uid: e4blflxy

Whether kidney transplant recipients are capable of mounting an effective anti‐SARS‐CoV‐2 adaptive immune response despite chronic immunosuppression is unknown and has important implications for therapy. Herein, we analyzed peripheral blood cell surface and intracellular cytokine phenotyping by flow cytometry along with serum antibody testing in 18 kidney transplant recipients with active COVID‐19 infection and 36 matched, transplanted controls without COVID‐19. We observed significantly fewer total lymphocytes, fewer circulating memory CD4(+) and CD8(+) T cells in the COVID‐19 subjects. We also showed fewer anergic and senescent CD8(+) T cells in COVID‐19 individuals, but no differences in exhausted CD8(+) T cells, nor in any of these CD4(+) T cell subsets between groups. We also observed greater frequencies of activated B cells in the COVID‐19 patients. Sixteen of 18 COVID‐19 subjects tested for anti‐SARS‐CoV‐2 serum antibodies showed positive IgM or IgG titers. Additional analyses showed no significant correlation s among immune phenotypes and degrees of COVID‐19 disease severity. Our findings indicate that immunosuppressed kidney transplant recipients admitted to the hospital with acute COVID‐19 infection can mount SARS‐CoV‐2‐reactive adaptive immune responses. The findings raise the possibility that empiric reductions in immunosuppressive therapy for all kidney transplant recipients with active COVID‐19 may not be required.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of the clinical illness Coronavirus disease 2019 (COVID- 19) , was first described in humans in December 2019 in Wuhan, China and has led to a global pandemic. 1 Among the risk factors for poor outcome are advanced age, presence of comorbidities such as hypertension, cardiovascular disease, diabetes, lung disease, and obesity. Chronic kidney disease, tumor and dysfunction of the immune system seem to be additional risk factors for developing complications during COVID- 19. 2 Immunosuppressed kidney transplant recipients are potentially at risk for poor outcome following COVID-19 infection, but relatively little has been reported in this population.

Mortality across kidney transplant recipients with COVID-19 is still unclear. While some US studies reported high mortality rates (about 20-30%) 3,4 , a European study showed a reduced mortality in transplanted patients with COVID-19 compared to the general population (9.5% vs. 12.5%, respectively). 5 Due to the possibility that immunosuppression may inhibit development of protective anti-COVID-19 immunity, many centers empirically reduce anti-rejection immunosuppression upon hospital admission for COVID-19 infection. As immunosuppression reduction increases the risk of graft rejection, understanding whether transplant recipients can mount immune responses to COVID-19 has important implications for devising best practice strategies in these patients. In an effort to address this unmet medical need, herein we set out to analyze peripheral blood immune cell phenotypes and serum antibodies in kidney transplant recipients hospitalized with acute COVID-19 infection and compare them to those of stable controls without COVID-19.

This article is protected by copyright. All rights reserved

We included 18 kidney transplant recipients admitted at Mount Sinai Hospital due to active COVID-19 from March 24 to May 10, 2020. The positivity for SARS-CoV-2 was diagnosed through real-time PCR (RT-PCR) of nasopharyngeal swab samples. We obtained serial samples from three subjects collected at least 23 days apart during admission. We recorded epidemiological, clinical and laboratory data.

As controls, we used previously biobanked samples from COVID-19 negative stable kidney transplant outpatients collected at the University Hospital in Verona, Italy (n = 8) or PBMC from subjects (n = 28) enrolled in the ongoing multicenter CTOT-19 trial (NCT02495077). In CTOT-19, recipients of deceased donor kidneys with Kidney Donor Profile Index scores 20% to 90% were treated with ATG induction and randomized to receive a single intra-operative infusion of anti-TNF monoclonal antibody infliximab (Remicade, Janssen, Beerse, Belgium) or saline. Maintenance immunosuppression consisted of tacrolimus, mycophenolate mofetil and prednisone. As the 2-year follow-up is not completed for all enrollee, the study remains blinded to the perioperative intervention. However, since infliximab half-life is <2 weeks 6 and samples included in this study were collected >4 months after induction, it is unlikely that this treatment affected immune phenotype of enrollees. We chose COVID-19 negative controls by matching for sex, age (± 10 years), and time after transplant (< 6 months; 6 -12 months; > 12 months) with the COVID-19 positive cases.

We collected data using an ad hoc database with the appropriate approval of the Ethics and Scientific Committees of the participating centers (IRB titles/numbers: IRB-20-03454, Mount Sinai Hospital; EudraCT: 2013-004538-14, University of Verona; CTOT-19 participating sites obtained approval by IRBs at the participating sites). We obtained serum levels of IL-6, C reactive protein, and ferritin on the day of blood collection from the clinical laboratory data at each participating center.

As additional controls, we used COVID-19 negative (n = 14) and positive (n = 16) individuals from the general population admitted at Mount Sinai Hospital, New York.

Whole blood samples from these individuals were analyzed by time-of-flight mass

This article is protected by copyright. All rights reserved cytometry (CyTOF). 7 Supplemental Table 1 includes a list of the markers we used for these analyses.

Flow cytometry analyses and Anti-SARS-CoV-2 antibody measurements are detailed in supplemental methods.

We expressed results as mean and standard deviation or standard error unless stated otherwise. Comparison of continuous variables between groups was performed by unpaired T test and categorical variables by two-sided chi-square or two-sided Fisher's exact test, where applicable. p < 0.05 was considered as statistically significant. No correction was made for multiple testing. Statistical analysis was performed using GraphpadPrism ® version 8.4.2 software package (Graphpad Software Inc., San Diego, CA). (Table 1) . CRP, D-dimer, and ferritin levels were all above normal ranges in COVID-19 patients ( Table 2) . Analysis of serum IL-6 levels (a proinflammatory mediator) in the COVID-19 positive subjects revealed median values of

This article is protected by copyright. All rights reserved 237.5 pg/ml (95%CI: 55.3 -422.7) ( Table 2 ) that are remarkably higher than those reported by others in stable, noninfected, kidney transplant recipients (<5 pg/ml). 8 Over a median (IQR) follow-up of 86.5 days (IQR: 81.5 -97.8) since admission, 7 COVID-19 patients died and 11 were discharged. No patients developed biopsy-proven acute rejection during this period, but 16 patients showed acute renal graft injury ( Table   2) . Naïve, effector, memory, dysfunctional, and regulatory CD4 + T cell subsets We did not detect differences in frequencies of CD4 + CD25 + CD127 low T REG or CD4 + CCR4 + CD45RA -CD25 + CD127 low activated T REG 10 between COVID-19 and controls Previous work by others studying non-transplanted COVID-19 patients with severe disease showed the emergence of dysfunctional (exhausted, anergic or senescent) T cells that could negatively impact outcomes. 11 When we quantified CD4 + T cells with phenotypic characteristics of exhaustion (KLRG1 + PD-1 + CD57 -), anergy (KLRG1 -PD-1 + CD57 -), or senescence (KLRG1 + PD-1 -CD57 + ) we did not detect differences between groups (Figure 2f-h; Supplementary Figure 1d ).

This article is protected by copyright. All rights reserved Naïve, effector, memory, and dysfunctional CD8 + T cells Analysis of CD8 + T cell subsets similarly revealed no differences in naïve or effector subsets between groups (Figure 3a-b) , although we observed fewer circulating memory CD8 + T cells in the COVID-19 subjects (Figure 3c ). While we did not observe differences in phenotypically exhausted CD8 + T cells between COVID-19 and control subjects (Figure 3d) , our analyses interestingly showed fewer anergic and senescent CD8 + T cells in COVID-19 enrollee (Figure 3e-f ).

Follicular helper T cells (T FH ) promote class switch recombination and affinity maturation in germinal centers, 12 are essential for rapid IgG antibody production in response to Ebola virus 13, 14 and influenza virus, 14 and are likely needed for development of effective anti-COVID-19 antibody responses.

When we quantified peripheral blood CD4 + CXCR5 + PD-1 + T FH by flow cytometry (gating strategy Supplemental Figure 3) , we did not observe significant differences between the two groups (Figure 4a) . We also did not observe significant differences in the frequencies of CD4 + CXCR5 + PD-1 + CCR6 -CXCR3 + T FH1 cells (implicated as crucial in antiviral antibody responses 15 ), CD4 + CXCR5 + PD-1 + CCR6 -CXCR3 -T FH2 cells (important for maturation of B cells into IgG4-secreting cells 16 ), nor in the CD4 + CXCR5 + PD-1 + CCR6 + CXCR3 -T FH17 cells 17 between groups (Figure 4b-d) . Figure 4 ) showed higher frequencies of total B cells and all B cell subsets [including transitional (IgD + CD27 -CD19 + ), switched memory (IgD -CD27 + CD19 + ), switched/activated (CD21 -CD95 + CD24 -IgD -CD27 + CD19 + ), recently activated (CD19 + CD21 + ) and B REG (CD25 high CD71 high CD19 + )] in COVID-19 subjects compared to controls (Figure 4e-j) . Analysis of percentages of peripheral blood plasma cells (CD19 + CD38 high CD27 high CD138 + ) and plasmablasts (CD19 + CD38 high CD27 high CD138 -) showed no differences between groups (data not shown).

This article is protected by copyright. All rights reserved

To assess whether these immunosuppressed kidney transplant recipients could mount an antibody response to SARS-CoV-2, we measured specific IgM and IgG antibodies by ELISA in 16 patients with available sera. When we plotted anti-SARS-CoV-2 IgM and IgG over time after symptoms, we noticed that most patients developed anti-virus antibodies starting 10 days after the symptom onset (Figure 4k-l) .

We did not observe significant differences in the incidence of anti-SARS-CoV-2 (60.0% vs. 36.4%, respectively; P: 0.6) or IgG (60.0% vs. 63.6%; P: >0.9) in subjects who underwent MMF/MPA withdrawal vs. those who maintained MMF/MPA.

To test whether immune phenotypes associate with disease severity of disease (Supplemental methods), we stratified patients into 3 groups, low-(score 3-4), intermediate-(score = 5), and high-risk (score  6) 18 , and we compared the percentages of each T and B cell subset and anti-SARS-CoV-2 IgM and IgG across patients in the three categories ( Table 2 ), noting that IL-6, a marker of inflammation, was highest in patients with most severe disease ( Table 2) .

We did not detect significant differences across the three groups for any of the analyzed T and B cell subsets (Figure 5a Notably, the PD1 + T cell subsets did not produce cytokines, verifying their dysfunctional status (Supplemental Figure 2) . Altogether, these data indicate that the immune changes in COVID-19 patients were independent of disease severity, at least in hospitalized patients.

To assess the variations in COVID-19 immune response over time, we analyzed changes in the immune phenotype in serial samples from three COVID-19 kidney transplant recipients. Overall, data from these three patients suggest a trend towards lower percentages of circulating Treg, exhausted T cells, B cell subsets, and anti-SARS-CoV-2

IgG levels. Interestingly, the absolute numbers of circulating T cells increased in the two

This article is protected by copyright. All rights reserved patients who were successfully discharged, while they remained low in the patient who died (COVIDTX32) (Figure 6 ).

Finally, we tested whether the above described immune changes associated with COVID-19 infection were unique to kidney transplant recipients or are similarly present in infected individuals in the general (non-transplanted) population. To address this issue, we analyzed samples from 16 individuals admitted for COVID-19 at Mount Sinai Hospital and 14 healthy controls (Supplemental Table 3 ). These samples were analyzed by CyTOF (as part of a concerted multi-PI effort within the institution), a technology that generates data that correlates well with data obtained by flow cytometry. 19 Similar to findings in kidney transplant recipients, we observed that COVID-19 individuals in the general population showed higher frequencies of active B cells (CD19 + CD27 + ) compared to healthy controls (Figure 7) . At variance from transplant recipients, individuals from the general population with COVID-19 showed increased Treg ( Figure   7 ).

Our unique analysis of peripheral blood immune phenotypes in a cohort of COVID-19 infected kidney transplant recipients provides evidence that these individuals are capable of developing an adaptive immune response to SARS-CoV-2 despite immunosuppression to prevent graft rejection. We observed higher serum IL-6, broad activation of B cell subsets, and detectable serum anti-SARS-CoV-2 IgM and IgG as early as 10 days after the onset of clinical symptoms in the majority of COVID-19 kidney transplant recipients, findings similar to those reported by others in COVID-19-infected but non-transplanted subjects. 20 We did not detect differences in circulating plasma cells or plasmablasts in our subjects. As the majority of antibody secreting cells are sequestered in the spleen or bone marrow, 21 it is not surprising that similar frequencies of these cells are detected in the circulation of transplanted subjects with and without COVID-19 infection. In a separate cohort of non-transplant patients with COVID-19, we

This article is protected by copyright. All rights reserved also found a significant increase in active B cells, indicating that immune changes observed in transplant recipients on chronic immunosuppression are similar to those observed in the general population.

While MMF/MPA was withdrawn in 5/18 subjects at the time of hospitalization (Table 1) , these changes did not appear to impact the development of SARS-CoV-2-specific antibodies, but longer follow-up and additional analyses will be required to determine whether the subjects have truly developed protective, memory immunity.

The COVID-19 transplant patients in our study developed lymphopenia, similar to data reported by others in non-transplanted patients. 1 Progressive lymphodepletion has been associated with clinical deterioration COVID-19 infection, whereas recovery of lymphocyte counts tended to directly precede clinical recovery. 22 The cross-sectional nature of our study prevents to formally test whether the same trends occur also in kidney transplant recipients. However, the inverse relationship between disease severity and lymphocyte numbers ( Table 2) suggests that a similar phenomenon occurs in transplant recipients. Intriguingly, in the three patients with serial samples analyzed in the present study, progressive lymphocyte decline was observed only in the patient with fatal outcome.

We found fewer memory CD8 + T cells in COVID-19 kidney transplant recipients compared to COVID-19 negative controls. Consistent with experimental data in mice infected with influenza, 23 it is possible that anti-viral CD8 + T cells are recruited into the lungs and other sites of SARS-CoV-2 infection. Our data indicate that kidney transplant recipients have fewer CD4 + and CD8 + IL-17 + T cells in the circulation. Similar to CD8 + memory T cells, it is possible that these cells are recruited in peripheral tissues. IL-17 has been implicated in the pathogenesis of COVID-19 also in non-transplanted patients. 24

The fact that IFN-, IL-2, and TNF- CD4 + and CD8 + T cells did not differ between COVID-19 positive and negative patients speaks against a skew in T cell polarization, but more studies are needed to better understand this mechanism.

We interestingly found no evidence that COVID-19 promotes T cell dysfunction in our study subjects. Exhaustion and other forms of T cell dysfunction are commonly observed in chronic viral infections and can be detrimental for viral clearance. 25 Patients in our Accepted Article study developed disease ~2 weeks prior to blood collection, leaving a limited amount of time for the development of exhaustion. Quite surprisingly, others have found signs of T cell exhaustion in early phases of COVID-19 infection and suggested a causal link between T cell exhaustion and progression. 26 Based on these findings, 26 we stained CD4 + and CD8 + T cells for TIM3 and LAG3, additional markers of T cell exhaustion, but we did not detect any association between disease severity and CD4 + or CD8 + PD1 + TIM3 + or PD1 + LAG3 + T cells (not shown). It is tempting to speculate that immunosuppressive therapy, while allowing the formation of an adaptive immune response, prevents/delays the onset of T cell dysfunction, but more studies are needed to formally test this hypothesis.

In kidney transplant recipients, we found that, similar to the general population, 1 COVID-19 was associated with a significant increase in inflammatory markers, including IL-6, CRP, ferritin, and D-dimer. Importantly the ratio between neutrophils and lymphocytes, a major risk factor for mortality in the general population, 27 was also significantly higher in more severe cases of COVID-19 ( Table 2) . Altogether, this data indicates that COVID-19 is associated with a significant inflammatory response also in kidney transplant recipients, despite ongoing chronic immunosuppression.

Intriguingly, we found a significant increase in circulating Treg in COVID-19 individuals from the general population that was not present in kidney transplant recipients. Others have shown a similar increase in Treg in COVID-19 subjects from the general population. 28 Lack of Treg expansion in kidney transplant recipients may be due to the use of calcineurin inhibitors that prevent Treg induction, 29 but more studies are needed to test this hypothesis. Others have shown that SARS-Cov-2-specific cells represent less than 1% of the total CD4 + and CD8 + T cells. 30 Therefore, it is likely that the changes in frequencies of circulating lymphocytes that we report are in fact not driven mainly by SARS-CoV-2 specific cells, but rather part of an overall activation of the adaptive immune response.

In summary, our findings indicate that stable kidney transplant recipients on maintenance CNI-based immunosuppression are capable of developing immune responses to SARS-CoV-2 that at least early on are similar to those observed in the general population.

Importantly, immunosuppression reduction/withdrawal was almost invariably associated with graft impairment, although no patients performed a biopsy to document the presence

This article is protected by copyright. All rights reserved of acute rejection. Nonetheless, results of controlled prospective trials will be required to definitively address this clinically significant treatment decision.

This article is protected by copyright. All rights reserved

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The authors sincerely thank the CTOT-19 site investigators and staff for their efforts, 

This article is protected by copyright. All rights reserved Cell. 2020;181 (7):1489-1501.e15.

Additional supporting information may be found online in the Supporting Information section at the end of the article.

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Characteristics of Coronavirus Disease 2019 in China

COVID-19 in solid organ transplant recipients: Initial report from the US epicenter

COVID-19 and Kidney Transplantation: Results from the TANGO International Transplant Consortium

First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study

Clinical Pharmacokinetics and Use of Infliximab

T-cell exhaustion correlates with improved outcomes in kidney transplant recipients

Evaluation of Serum Interleukin-6 Levels in the Renal Transplant Recipients: A Systematic Review and Meta-Analysis of Case-Control Studies. Open Access Maced

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells

Accepted Article This article is protected by copyright. All rights reserved

The trinity of COVID-19: immunity, inflammation and intervention

Follicular Helper CD4 T Cells (T FH )

Human Ebola virus infection results in substantial immune activation

Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination

Frequencies of Circulating Th1-Biased T Follicular Helper Cells in Acute HIV-1 Infection Correlate with the Development of HIV-Specific Antibody Responses and Lower Set Point Viral Load

Follicular helper T cells in the pathogenesis of IgG4-related disease

Role of the frequency of blood CD4+ CXCR5+ CCR6+ T cells in autoimmunity in patients with Sjögren's syndrome

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Mass Cytometry: Single Cells, Many Features

Antibody responses to SARS-CoV-2 in patients with COVID-19

Characteristics of natural antibody-secreting cells: Natural antibody secretion

Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients. medRxiv